These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568 [TBL] [Abstract][Full Text] [Related]
4. Bioresorbable vascular scaffolds in left main coronary artery disease. Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. Wiebe J; Baquet M; Dörr O; Hoppmann P; Jochheim D; Rheude T; Boeder N; Grundmann D; Blachutzik F; Theiss H; Cassese S; Hofmann FJ; Gschwendtner S; Elsässer A; Massberg S; Hamm C; Laugwitz KL; Byrne RA; Mehilli J; Kastrati A; Nef H Int J Cardiol; 2020 Aug; 312():42-47. PubMed ID: 32151443 [TBL] [Abstract][Full Text] [Related]
6. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound. Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Tanaka A; Naganuma T; Sticchi A; Chieffo A; Carlino M; Montorfano M; Colombo A Catheter Cardiovasc Interv; 2017 Apr; 89(5):789-797. PubMed ID: 27545845 [TBL] [Abstract][Full Text] [Related]
7. Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. Boeder NF; Johnson V; Dörr O; Wiebe J; Elsässer A; Möllmann H; Hamm CW; Nef HM; Bauer T Int J Cardiol; 2017 Mar; 231():73-77. PubMed ID: 27899203 [TBL] [Abstract][Full Text] [Related]
8. Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation. Tanaka A; Jabbour RJ; Kawamoto H; Mangieri A; Pagnesi M; Montalto C; Chieffo A; Carlino M; Montorfano M; Latib A; Colombo A Catheter Cardiovasc Interv; 2016 Nov; 88(6):865-870. PubMed ID: 27219102 [TBL] [Abstract][Full Text] [Related]
9. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. Fazel R; Vilain KA; Cohen DJ; Yeh RW Coron Artery Dis; 2020 May; 31(3):230-236. PubMed ID: 31658137 [TBL] [Abstract][Full Text] [Related]
10. Paving the way to a bioresorbable technology: Development of the absorb BRS program. Perkins LE; Kossuth MB; Fox JC; Rapoza RJ Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462 [TBL] [Abstract][Full Text] [Related]
15. Bioresorbable vascular scaffold in patients with complex coronary artery disease. Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353 [TBL] [Abstract][Full Text] [Related]
16. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973 [TBL] [Abstract][Full Text] [Related]
17. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. Ielasi A; Tespili M Future Cardiol; 2014 May; 10(3):409-20. PubMed ID: 24976477 [TBL] [Abstract][Full Text] [Related]
19. When and how to use BRS in bifurcations? Stankovic G; Lassen JF EuroIntervention; 2015; 11 Suppl V():V185-7. PubMed ID: 25983163 [TBL] [Abstract][Full Text] [Related]
20. Bioresorbable scaffold -fourth revolution or failed revolution: Is low scaffold strut thickness the wrong target? Mishra S Indian Heart J; 2017; 69(6):687-689. PubMed ID: 29174242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]